Nkarta, Inc. Payments to Acquire Debt Securities, Available-for-sale
Nkarta, Inc. (NKTX) reported Payments to Acquire Debt Securities, Available-for-sale of $385.89 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2023-03-16
- Nkarta, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $385.89M, a 69.78% increase from fiscal 2021.
- Nkarta, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $227.28M, a 2.12% increase from fiscal 2020.
- Nkarta, Inc. payments to acquire debt securities, available-for-sale for fiscal 2020 was $222.57M, a 1259.87% increase from fiscal 2019.
- Nkarta, Inc. payments to acquire debt securities, available-for-sale for fiscal 2019 was $16.37M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|
| 2022-12-31 | $385.89M 10-K · filed 2023-03-16 |
| 2021-12-31 | $227.28M 10-K · filed 2023-03-16 |
| 2020-12-31 | $222.57M 10-K · filed 2022-03-17 |
| 2019-12-31 | $16.37M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |